Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Cloxacillin - Wikipedia
Cloxacillin - Wikipedia
From Wikipedia, the free encyclopedia
Beta-lactam antibiotic
Pharmaceutical compound
Cloxacillin
Clinical data
Trade namesCloxapen, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
By mouth, IM
ATC code
  • J01CF02 (WHO) QJ51CF02 (WHO) QS01AA90 (WHO)
Pharmacokinetic data
Bioavailability37 to 90%
Protein binding95%
Elimination half-life30 minutes to 1 hour
Excretionkidney and biliary
Identifiers
IUPAC name
  • (2S,5R,6R)-6-{[3-(2-chlorophenyl)-5-methyl-
    oxazole-4-carbonyl]amino}-3,3-dimethyl-7-oxo-
    4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid or 5 methyl 3(2 chlorophenyl)4 isoxazoyl penicillin
CAS Number
  • 61-72-3 checkY
PubChem CID
  • 6098
DrugBank
  • DB01147 checkY
ChemSpider
  • 5873 checkY
UNII
  • O6X5QGC2VB
KEGG
  • D07733 checkY
ChEBI
  • CHEBI:49566 checkY
ChEMBL
  • ChEMBL891 checkY
CompTox Dashboard (EPA)
  • DTXSID5022853 Edit this at Wikidata
ECHA InfoCard100.000.468 Edit this at Wikidata
Chemical and physical data
FormulaC19H18ClN3O5S
Molar mass435.88 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1ccccc1Cl)C)[C@H]4SC3(C)C
InChI
  • InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1 checkY
  • Key:LQOLIRLGBULYKD-JKIFEVAISA-N checkY
  (verify)

Cloxacillin is an antibiotic useful for the treatment of several bacterial infections.[1] This includes impetigo, cellulitis, pneumonia, septic arthritis, and otitis externa.[1] It is not effective for methicillin-resistant Staphylococcus aureus (MRSA).[2] It can be used by mouth and by injection.[1]

Side effects include nausea, diarrhea, and allergic reactions including anaphylaxis.[1] Clostridioides difficile diarrhea may also occur.[2] It is not recommended in people who have previously had a penicillin allergy.[1] Use during pregnancy appears to be relatively safe.[1] Cloxacillin is in the penicillin family of medications.[2]

Cloxacillin was patented in 1960 and approved for medical use in 1965.[3] It is on the World Health Organization's List of Essential Medicines.[4] It is not commercially available in the United States.[2]

Mechanism of action

[edit]

It is semisynthetic and in the same class as penicillin. Cloxacillin is used against staphylococci that produce beta-lactamase, due to its large R chain, which does not allow the beta-lactamases to bind. This drug has a weaker antibacterial activity than benzylpenicillin, and is devoid of serious toxicity except for allergic reactions.[citation needed]

Society and culture

[edit]

Cloxacillin was discovered and developed by Beecham (now GlaxoSmithKline).[5]

It is sold under a number of trade names, including Cloxapen, Cloxacap, Tegopen and Orbenin.[6]

See also

[edit]
  • Dicloxacillin
  • Flucloxacillin
  • Nafcillin
  • Oxacillin

References

[edit]
  1. ^ a b c d e f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 98, 100, 110–111, 586, 602, 614, 623. hdl:10665/44053. ISBN 9789241547659.
  2. ^ a b c d "Cloxacillin (Professional Patient Advice)". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 490. ISBN 9783527607495. Archived from the original on 2016-12-20.
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ Greenwood D (2008). Antimicrobial drugs: chronicle of a twentieth century medical triumph. Oxford University Press US. pp. 124–. ISBN 978-0-19-953484-5. Archived from the original on 6 June 2013. Retrieved 18 November 2010.
  6. ^ Gollakner R (2023-05-09). "Cloxacillin". VCA Animal Hospitals. Retrieved 2023-05-09.

External links

[edit]
  • "Cloxacillin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on October 23, 2021.
  • v
  • t
  • e
Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases
)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
  • Benzylpenicillin (G)#
  • Benzathine benzylpenicillin#
  • Procaine benzylpenicillin#
  • Phenoxymethylpenicillin (V)#
  • Propicillin‡
  • Pheneticillin‡
  • Azidocillin‡
  • Clometocillin‡
  • Penamecillin‡
β-lactamase resistant
(2nd generation)
  • Cloxacillin# (Dicloxacillin
  • Flucloxacillin)
  • Oxacillin
  • Nafcillin
  • Methicillin‡
Extended
spectrum
Aminopenicillins (3rd generation)
  • Amoxicillin#
  • Ampicillin# (Pivampicillin
  • Hetacillin‡
  • Bacampicillin‡
  • Lenampicillin
  • Metampicillin‡
  • Talampicillin‡)
  • Epicillin‡
Carboxypenicillins (4th generation)
  • Ticarcillin
  • Carbenicillin‡ / Carindacillin‡
  • Temocillin‡
Ureidopenicillins (4th generation)
  • Piperacillin
  • Azlocillin‡
  • Mezlocillin‡
Other
  • Mecillinam (Pivmecillinam)
  • Sulbenicillin‡
Carbapenems / Penems
  • Carbapenems (Ertapenem
  • Antipseudomonal (Doripenem
  • Imipenem
  • Meropenem)
  • Biapenem‡
  • Panipenem)
  • Penems (Faropenem
  • Ritipenem§
  • Sulopenem)
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
  • Cefazolin#
  • Cefalexin #
  • Cefadroxil
  • Cefapirin
  • Cefazedone‡
  • Cefazaflur‡
  • Cefradine‡
  • Cefroxadine‡
  • Ceftezole‡
  • Cefaloglycin‡
  • Cefacetrile‡
  • Cefalonium‡
  • Cefaloridine‡
  • Cefalotin
  • Cefatrizine‡
2nd generation
  • Cefaclor
  • Cefprozil
  • Cefuroxime
  • Cefuroxime axetil
  • Cefamandole‡
  • Cefonicid‡
  • Ceforanide‡
  • Cefuzonam‡
  • Cephamycin (Cefoxitin
  • Cefotetan
  • Cefminox‡
  • Cefbuperazone‡
  • Cefmetazole‡)
  • Carbacephem (Loracarbef‡)
3rd generation
  • Cefixime#
  • Ceftriaxone#
  • Cefotaxime#
  • Antipseudomonal (Ceftazidime#
  • Cefoperazone)
  • Cefdinir
  • Cefcapene
  • Cefdaloxime
  • Ceftizoxime
  • Cefmenoxime
  • Cefpiramide
  • Cefpodoxime
  • Ceftibuten
  • Cefditoren
  • Cefotiam‡
  • Cefetamet‡
  • Cefodizime‡
  • Cefpimizole‡
  • Cefsulodin‡
  • Cefteram‡
  • Ceftiolene‡
  • Oxacephem (Flomoxef
  • Latamoxef‡)
4th generation
  • Cefepime
  • Cefozopran‡
  • Cefpirome
  • Cefquinome‡
5th generation
  • Ceftaroline fosamil
  • Ceftolozane
  • Ceftobiprole
Siderophore
  • Cefiderocol#
Veterinary
  • Ceftiofur
  • Cefquinome
  • Cefovecin
Monobactams
  • Aztreonam
  • Tigemonam‡
  • Carumonam‡
  • Nocardicin A‡
β-lactamase inhibitors
  • Penam (Sulbactam
  • Tazobactam
  • Enmetazobactam)
  • Clavam (Clavulanic acid)
  • non-β-lactam (Avibactam
  • Durlobactam
  • Relebactam
  • Taniborbactam
  • Vaborbactam)
Combinations
  • Amoxicillin/clavulanic acid#
  • Ampicillin/flucloxacillin
  • Ampicillin/sulbactam (Sultamicillin)
  • Aztreonam/avibactam
  • Benzathine benzylpenicillin/procaine benzylpenicillin
  • Cefepime/enmetazobactam
  • Cefepime/sulbactam
  • Cefoperazone/sulbactam
  • Ceftazidime/avibactam
  • Ceftolozane/tazobactam
  • Imipenem/cilastatin#
  • Imipenem/cilastatin/relebactam
  • Meropenem/vaborbactam
  • Panipenem/betamipron
  • Piperacillin/tazobactam
  • Sulbactam/durlobactam
  • Sulopenem/probenecid
  • Ticarcillin/clavulanic acid
Polypeptides
Lipopeptides
  • Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
  • Surfactin
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
  • Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
    • Fosfomycin
  • DADAL/AR inhibitors
    • Cycloserine
    • Terizidone
  • bactoprenol inhibitors
    • Bacitracin
Other
  • Hydrolyze NAM-NAG
    • Lysozyme
  • Tyrothricin
    • Gramicidin
    • Tyrocidine
  • Isoniazid#
  • Teixobactin
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III
Portal:
  • icon Medicine
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Cloxacillin&oldid=1301005953"
Categories:
  • 2-Chlorophenyl compounds
  • Enantiopure drugs
  • Isoxazoles
  • Penicillins
  • World Health Organization essential medicines
Hidden categories:
  • CS1:Vancouver names with accept markup
  • Articles with short description
  • Short description is different from Wikidata
  • ECHA InfoCard ID from Wikidata
  • Drugs with no legal status
  • All articles with unsourced statements
  • Articles with unsourced statements from January 2023
  • Wikipedia medicine articles ready to translate

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id